ANI Pharmaceuticals Fights Alimera Sciences Lawsuit to Compel Closing of Merger
September 10, 2024
Alimera Sciences filed a lawsuit in Delaware Court of Chancery seeking to compel ANI Pharmaceuticals to close their previously announced merger under the June 21, 2024 Agreement and Plan of Merger. Alimera says it satisfied its own closing requirements and that its shareholders approved the transaction on September 4, 2024, while ANI allegedly failed to close on time.
- Buyers
- ANI Pharmaceuticals, Inc.
- Targets
- Alimera Sciences, Inc.
- Industry
- Pharmaceuticals
- Location
- Georgia, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences
April 10, 2024
Biotechnology
Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.
-
MEI Pharma and Infinity Pharmaceuticals Announce Definitive All-Stock Merger
February 24, 2023
Pharmaceuticals
MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc. entered into a definitive merger agreement for an all-stock transaction to form a combined clinical-stage oncology company. The merged organization will advance a pipeline of three clinical-stage oncology drug candidates, including eganelisib, voruciclib, and ME-344.
-
Alcon Acquires Aerie Pharmaceuticals, Inc.
August 22, 2022
Healthcare Services
Alcon entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, adding Rocklatan and Rhopressa commercial products along with AR-15512 and other ophthalmic pharmaceutical pipeline assets. The deal was funded with debt and was expected to close in Q4 2022, subject to customary approvals and conditions.
-
ANI Pharmaceuticals Acquires Four ANDAs from Oakrum Pharma, LLC
July 28, 2022
Pharmaceuticals
ANI Pharmaceuticals, Inc. acquired four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC in an asset purchase announced July 28, 2022. The acquisition expands ANI's generics product portfolio and is intended to enable product launches and revenue contribution beginning in 2023.
-
ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M
March 9, 2021
Pharmaceuticals
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
-
Altasciences Acquires Alliance Contract Pharma
February 27, 2020
Pharmaceuticals
Altasciences, a mid-size contract research organization based in Laval, Quebec, has acquired Alliance Contract Pharma to add small-molecule contract manufacturing and analytical services, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution. The acquisition expands Altasciences' integrated early‑phase drug development offering by adding manufacturing and analytical capabilities to its preclinical, clinical, and bioanalytical services.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.